ICMR begins study on vaccine for people with poor immunity

Indian Council of Medical Research (ICMR), the country’s top health research body, has initiated a study to evaluate the effectiveness of Covid-19 vaccines in immunocompromised people. Experts say the results are likely in the next six months. The study includes some people with kidney related problems and some on dialysis, among others, they said.

“This way, we will get to know the magnitude of the problem,” said J Muliyil, a member of National Technical Advisory Group on Immunisation (NTAGI).

The study will see how immunocompromised people are responding to existing Covid-19 vaccines, including Covishield and Covaxin. It will also evaluate the effect of a booster shot on these people when it is the same as the one given earlier and also when it’s a different vaccine.

“The study will evaluate how they are responding to vaccines and how giving them a booster dose of the same vaccine and a different vaccine will work,” said Muliyil.

Prime Minister Narendra Modi on Saturday announced that booster shots should be administered to health and frontline workers and those above 60 with comorbidities from January 10. He also said vaccinations will begin for children between 15 and 18 years from January 3.

While the announcement comes as a relief to many, experts say data is needed.

“We have to see whether people who are immunocompromised due to associated disease conditions cannot mount enough immune response. Studies are needed to understand the same and data is generated to see the response of the available vaccines in immunocompromised people,” said an expert at ICMR.

  • Related Posts

    Gene Therapy for Cholesterol: Initial Test Results Cheer

    Eli Lilly working on single-dose drug to be administered via IV for long-term gain Mumbai: For millions of heart patients struggling with elevated levels of cholesterol, there is a ray…

    US Biotech Regeneron to launch Global Capability Centre in Hyderabad

    Regeneron Pharmaceuticals, Inc. has announced plans to establish the Regeneron Global Capability Centre (GCC) in Hyderabad, a strategic investment that deepens its global operations and scales business functions to advance…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Gene Therapy for Cholesterol: Initial Test Results Cheer

    Gene Therapy for Cholesterol: Initial Test Results Cheer

    US Biotech Regeneron to launch Global Capability Centre in Hyderabad

    US Biotech Regeneron to launch Global Capability Centre in Hyderabad

    Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

    Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

    Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

    Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

    Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

    Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

    STF busts fake meds racket spread across 6 states

    STF busts fake meds racket spread across 6 states